EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoi...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
U.S. Pharmaceutical Intellectual Property Strategy: Patents, Exclusivity and Competitive Protection
Bringing a new drug to market can cost over a billion dollars and take a decade or more Copying that drug can cost a tiny fraction of that Without legal protection no company could recover its investment and fewer new medicines would reach patients
-
Techno Trends
Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment
Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment
-
Projects
Genentech Begins US$750 Million Expansion of Oregon Manufacturing Facility
Genentech a member of the Roche Group has started construction on a US million expansion of its manufacturing facility in Hillsboro Oregon The squarefoot project will double the existing sites footprint and increase US production capacity for advanced drug delivery devices
-
Research Insights
Identification of flavonoids from natural products against hyperlipidaemia through computational approaches
Over the centuries hyperlipidaemia has been recognised as a major risk factor contributing to cardiovascular disease CVD Current research increasingly explores natural compounds such as flavonoids for their potential lipidlowering effects This study evaluated pharmacological potential
-
White Papers
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys complexity
TOP ARTICLES
-
1
Curcumin’s Role as an Anti-Neurofibrillary Agent Towards Alzheimer's Disease
Sabrina Ruoyao Chen Zhang
Ronny Priefer
Alzheimer’s disease is a progressive neurodegenerative disease that afflicts millions of people globally. Symptoms typically present as memory loss and cognitive decline. Existing hypthoses focu...
-
2
Closing the Bench-to-Bedside Gap: Biomarker Strategies That Actually De-Risk Development
Lakshmi
Roughly nine out of ten drug candidates that enter clinical testing never reach patients. The failure rate is brutal, and it clusters in the space where laboratory promise meets human biology—th...
-
3
AI Drug Discovery IP Strategy: Navigating Patent Challenges
Prof. (Dr.) Amrish Chandra
Artificial Intelligence is revolutionising drug discovery, offering unprecedented speed in target identification, compound optimisation, and clinical predictions. Yet, protecting these outputs through...
-
4
Analytical Strategies for Characterizing Complex Biologics and ADCs
Lakshmi
For decades, the pharmaceutical industry equated therapeutic ambition with the ability to design a promising molecule. That equation no longer holds. As portfolios pivot toward complex biologics and a...
-
5
Mastering Pharma Innovation: EU's Triumph over Advanced Manufacturing Challenges
Kate Williamson
In the dynamic realm of pharmaceuticals, the European Union (EU) has excelled in overcoming advanced manufacturing hurdles, showcasing prowess in innovation and collaboration. This article explores th...
press releasesRead more...
Egetis Therapeutics Announces U.S. Launch of EMCITATE® for Patients with MCT8 Deficiency
Egetis Therapeutics AB a commercialstage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases today announced the commercial availability of EMCITATE tiratricol ahead of anticipated timelines following US Food and Drug Administration FDA ap...
Rumi Therapeutics Announces Licensing Agreement With Enthorin Therapeutics to Advance RTX-7340, an IND-Ready PDE2 Inhibitor, for Fragile X Syndrome
Rumi Therapeutics a drugdevelopment company within Rumi Scientific Holdings today announced an option to license agreement with Enthorin Therapeutics to advance RTX ENT an investigational phosphodiesterase PDE inhibitor for the treatment of Fragile X syndrome FXS The agreement brings an INDready th...
Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
Pfizer Inc announced that the US Food and Drug Administration FDA has expanded approval of TALZENNA talazoparib in combination with XTANDI enzalutamide to the treatment of men with metastatic androgen pathway modulationnave or sensitive mAPMNS prostate cancer PC with homologous recombination repair...
Zef Scientific and Copia Scientific Partner to Deliver Automated Solutions for High-Throughput LC/MS Workflows: “From Sample Prep to LC/MS. Together”
Zef Scientific Inc ZefSci a provider of multivendor liquid chromatographymass spectrometry LCMS service and systems and Copia Scientific a fullservice laboratory automation equipment company today announced a partnership to provide complementary instrumentation workflow support and service for autom...
Events Read more...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX Korea
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
LATEST NEWSRead more...
Onco360® Has Been Selected as a National Pharmacy Partner for ZEGFROVY® (sunvozertinib)
Onco the nations leading independent Specialty Pharmacy has been selected as a national pharmacy partner by AstraZeneca Pharmaceuticals for Zegfrovy sunvozertinib which is indicated for the treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer NSCLC with epidermal...
Octant Receives FDA Orphan Drug Designation for OCT-980 for the Treatment of Retinitis Pigmentosa
Octant Inc Octant a clinicalstage drug discovery company developing correctors for protein misfolding diseases today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation to OCT for the treatment of retinitis pigmentosa RP The designation includes rhodopsinassoci...
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Regeneron Pharmaceuticals Inc announced today that it has extended its agreement with the Biomedical Advanced Research and Development Authority BARDA part of the Administration for Strategic Preparedness and Response ASPR within the US Department of Health and Human Services
Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug Delivery
Aptar Pharma a global leader in drug delivery dosing protection technologies and services today announced the strategic acquisition of PULMOTREE a Munich Germanybased life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs The acquisition is expected t...
Ignite Proteomics Enters Breast Cancer Research Collaboration with Leading Cancer Center
Ignite Proteomics Inc a precision oncology company focused on functional proteomics today announced it is collaborating with Memorial Sloan Kettering Cancer Center MSK to study protein signaling patterns associated with treatment response and resistance in advanced breast cancer
Warp Sciences Emerges From Stealth With $215 Million to Build U.S. Chemistry Services for Drug Research
Warp Sciences today emerged from stealth with million in funding to create the infrastructure that enables biotech and pharmaceutical companies to discover new medicines faster The company is building a USbased chemistry contract research organization CRO that brings expert chemists
